ncRNA basic information
ncRNA ID:
MIMAT0004597
ncRNA Database:
miRBase
ncRNA Name:
miR-140-3p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
PTEN
ncRNA Pathway:
PI3K-Akt-mTOR signaling pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Doxorubicin
Drug Method:
We aimed to investigate the mechanisms of these two miRNAs in chordoma cells. Patient-derived chordoma cell lines were established in vitro. Expressions of miR-140-3p or miR-155-5p were measured by quantitative real-time polymerase chain reaction and their functions were inhibited by antagomir treatment. Malignancy of chordoma cells was assessed by cell viability, proliferation, apoptosis, colony formation and transwell invasion assays as well as western blot evaluating epithelial-to-mesenchymal transition. Sensitivity of chordoma cells was assessed by cell viability and apoptosis assays. Protein level of phosphatase and tensin homolog (PTEN) and phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway were assessed by western blot. Interaction of miR-140-3p and miR-155-5p with the 3 untranslated region of PTEN mRNA was verified by luciferase reporter assay. BpV was used to inhibit PTEN activity.
Drug Response:
resistant
Cancer basic information
Cancer:
chordoma
Tissue/Cell:
cell line
Other information
Title:
Inhibition of miR-140-3p or miR-155-5p by antagomir treatment sensitize chordoma cells to chemotherapy drug treatment by increasing PTEN expression.
Journal:
Eur J Pharmacol
Published:
2019
PubMed ID:
30980798